Capecitabine For Nasopharyngeal Cancer

NCT00095901 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Capecitabine

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]